



大阪大学
放射線科学基盤機構セミナー

Targeted alpha therapy and theranostics in the future



Prof. Dr. Frederik L. Giesel
Dept of Nuclear Medicine,
Dusseldorf University

11月25日 金 14:00~15:00
(事前申込不要)

□ 会場

放射線科学基盤機構
附属ラジオアイソトープ総合センター
吹田本館 会議室

□ アクセス

大阪府吹田市山田丘2-4
吹田キャンパス



□ お問い合わせ

大阪大学大学院医学系研究科
渡部直史

MAIL

watabe@tracer.med.osaka-u.ac.jp

□ オンライン(Webex)アクセス

<https://osaka-u.webex.com/osaka-u/j.php?MTID=m11935b22ff2548564863609601700880>

ミーティング番号: 2516 229 9705
パスワード: A3Ps8JbT97x

Abstract

Nuclear Medicine is in a revolutionary era translating new innovative imaging probes and particular also theranostic applications to improve patient management and care.

Today, personalized medicine is one of the most important approach to improve patient treatment outcome and long lasting treatment effect. Nuclear medicine is a key player due to the matter that non-invasive patient phenotyping is possible to stratify treatment benefits using imaging-probes which later can be modified for further radio-pharmaceutical drug attacking on cellular level tumor cells and its micro-environment while sparing normal tissue.

Furthermore, ground-breaking translation work have supported the venue of utilizing instead of beta-emitter rather alpha-emitter to long lasting cancer treatment effects. Beta-Emitter in radiopharmaceuticals enables only single-strand-break, while alpha-emitter inducing double-strand-DNA breaks which often translate in direct cell death due to apoptosis and possible longer treatment duration. Many efforts have been made in science to introduce alpha-emitter into clinical environment, but often challenged by regulation, production chain and distribution channel.

This presentation will give an overview of the impact of alpha emitter in cancer, new targets and its recent development on a regional and global perspective.